Walmart, Costco and Amazon are positioned to play a larger role in how patients obtain GLP-1 weight-loss drugs such as Wegovy and Zepbound as more employers reduce or stop offering coverage for these treatments. Both outlets report that increased employer cost-cutting is pushing patients away from traditional insurance pathways and toward direct-to-consumer options. In this changing market, retailers and e-commerce platforms are competing to become a primary “front door” for consumers by offering prescribing and fulfillment approaches that support patients seeking GLP-1 medications outside employer-sponsored coverage. The coverage shifts are described as an ongoing driver of demand for direct purchasing and related services, including access to clinician evaluation and ongoing medication supply through retailer-linked programs. While the details of specific program structures are not uniform across sources, they agree on the direction of travel: diminished employer coverage increases the number of people who look to direct-to-consumer channels. The result is intensified competition among major retail and technology companies to attract and retain customers needing these drugs.